Brain-directed gene therapy for lysosomal storage disease: Going well beyond the blood– brain barrier
- 30 April 2002
- journal article
- editorial
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 99 (9) , 5760-5762
- https://doi.org/10.1073/pnas.102175599
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Reversal of Pathology in the Entire Brain of Mucopolysaccharidosis Type VII Mice after Lentivirus-Mediated Gene TransferHuman Gene Therapy, 2000
- Systemic Hyperosmolality Improves β-Glucuronidase Distribution and Pathology in Murine MPS VII Brain Following Intraventricular Gene TransferExperimental Neurology, 1999
- Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function.Journal of Clinical Investigation, 1998
- Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation.Journal of Clinical Investigation, 1997
- Enzyme replacement therapy for murine mucopolysaccharidosis type VII.Journal of Clinical Investigation, 1994
- Gene therapy on the SlyNature Genetics, 1993
- Behavioural abnormalities in a murine model of a human lysosomal storage diseaseNeuroReport, 1993
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991
- Invitro correction of deficient human fibroblasts by β-glucuronidase from different human sourcesBiochemical and Biophysical Research Communications, 1974
- Beta glucuronidase deficiency: Report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosisThe Journal of Pediatrics, 1973